TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21459796

Group type: EXPERIMENTAL
Intervention: GSK461364 administered intravenously at 300 mg (schedule A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GSK461364 administered intravenously at 225 mg (schedule A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GSK461364 administered intravenously at 100 mg (schedule B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GSK461364 administered intravenously (both schedules)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GSK461364 at 225 mg (schedule A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GSK461364 (both schedules)
Number of subjects: 40
Study: 21463526

Group type: EXPERIMENTAL
Intervention: Injectable risperidone long-acting therapy (RLAT)
Number of subjects: 3069
Study: 21463793

Group type: EXPERIMENTAL
Intervention: Esophageal stenting during neoadjuvant therapy
Number of subjects: 32
Study: 21463817

Group type: EXPERIMENTAL
Intervention: Admission estradiol (E(2))
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Subsequent estradiol (E(2))
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Changes in estradiol (E(2))
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Regression model performance
Number of subjects: 1408
Study: 21464053

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: β-blocker use
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy for atrial fibrillation
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: HF education for eligible patients
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist use
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: All-or-none care summary measure
Number of subjects: 15177

Group type: EXPERIMENTAL
Intervention: Composite care summary measure
Number of subjects: 15177
Study: 21464155

Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib after June 2007
Number of subjects: 882

Group type: COMPARATOR
Intervention: Adjuvant imatinib before June 2007
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Overall imatinib treatment
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Overall sunitinib treatment
Number of subjects: 882

Group type: COMPARATOR
Intervention: Imatinib utilization in 2006
Number of subjects: 882

Group type: COMPARATOR
Intervention: Sunitinib utilization in 2006
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Imatinib utilization in 2009
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Sunitinib utilization in 2009
Number of subjects: 882
Study: 21464430

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD) up to 80 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD)
Number of subjects: 23
Study: 21465636

Group type: EXPERIMENTAL
Intervention: Oral imatinib at 340 mg/m²
Number of subjects: 51
Study: 21467128

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no change in medication)
Number of subjects: 10
Study: 21467178

Group type: EXPERIMENTAL
Intervention: Glaucoma cohort (n = 87)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Cataract cohort (n = 38)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Forecasting method
Number of subjects: 309
Study: 21467546

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 75
Study: 21468300

Group type: EXPERIMENTAL
Intervention: Maternal triple-antiretroviral regimen (zidovudine, lamivudine, and either nevirapine or nelfinavir) from 34-36 weeks' gestation to 6 months postpartum
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Maternal triple-antiretroviral regimen
Number of subjects: 487
Study: 21468304

Group type: EXPERIMENTAL
Intervention: Nelfinavir-based regimen
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nevirapine-based regimen
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 32
Study: 21468309

Group type: EXPERIMENTAL
Intervention: Single 400 mg dose of albendazole (ALB)
Number of subjects: 7
Study: 21470010

Group type: EXPERIMENTAL
Intervention: XRX-001 vaccine (4.8 μg antigen)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: XRX-001 vaccine (0.48 μg antigen)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: XRX-001 vaccine (both dosages)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21470045

Group type: EXPERIMENTAL
Intervention: etravirine (ETR) 200 mg twice daily
Number of subjects: 28
Study: 21470813

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 1402
Study: 21471286

Group type: EXPERIMENTAL
Intervention: Gefitinib (500 mg for 5 days before surgery and continued postoperatively until recurrence)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control cohort (12 patients)
Number of subjects: 22
Study: 21471568

Group type: EXPERIMENTAL
Intervention: Gluten-free diet for 12 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Presence of intestinal anti-TG2 antibodies
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid-binding protein (I-FABP)
Number of subjects: 22
Study: 21473790

Group type: EXPERIMENTAL
Intervention: Vorinostat in combination with pelvic palliative radiotherapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vorinostat at the maximum-tolerated dose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 14
Study: 21474353

Group type: EXPERIMENTAL
Intervention: High dose glyceryl triacetate (GTA) at 4.5 g/kg/d for 4.5 and 6 months respectively
Number of subjects: 2

Group type: COMPARATOR
Intervention: Low dose glyceryl triacetate (GTA) at up to 0.25 g/kg/d
Number of subjects: 2
Study: 21474571

Group type: EXPERIMENTAL
Intervention: Chronic Bronchitis (CB+)
Number of subjects: 1061
Study: 21474664

Group type: EXPERIMENTAL
Intervention: TEG® parameters pre-CD
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: TEG® parameters post-CD
Number of subjects: 52
Study: 21474786

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily with food
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 300 mg twice daily
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU)
Number of subjects: 56
Study: 21474799

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (reperfusion)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (no reperfusion)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DWI analysis
Number of subjects: 111
Study: 21475009

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical therapy (Control)
Number of subjects: 30
Study: 21475026

Group type: EXPERIMENTAL
Intervention: Laparoscopic Kasai procedure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Kasai procedure
Number of subjects: 40
Study: 21475692

Group type: EXPERIMENTAL
Intervention: High-caloric (600 kcal) high-protein (20 g) oral nutritional supplement
Number of subjects: 29
Study: 21476613

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg twice daily)
Number of subjects: 31
Study: 21477202

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Simvastatin overall effect
Number of subjects: 26
Study: 21478218

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg) administered as two intravenous infusions 15 days apart
Number of subjects: 10
Study: 21478385

Group type: EXPERIMENTAL
Intervention: High on-clopidogrel platelet reactivity (HCPR)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: High on-aspirin platelet reactivity (HAPR)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Dual high on-treatment platelet reactivity (DAPR)
Number of subjects: 921

Group type: COMPARATOR
Intervention: No high on-treatment platelet reactivity
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: DAPR (VerifyNow system)
Number of subjects: 921

Group type: COMPARATOR
Intervention: No high on-treatment platelet reactivity (VerifyNow system)
Number of subjects: 921
Study: 21478502

Group type: EXPERIMENTAL
Intervention: Copenhagen Hip and Groin Outcome Score (HAGOS)
Number of subjects: 101
Study: 21478667

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imatinib and Nilotinib
Number of subjects: 0
Study: 21480191

Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg doses) with CYP3A4/P-glycoprotein inhibitors
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg doses) with azithromycin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg doses) with other CYP3A4/P-glycoprotein inhibitors
Number of subjects: 7
Study: 21480819

Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 670
Study: 21480935

Group type: EXPERIMENTAL
Intervention: Routine care management for NVUGIB
Number of subjects: 2660
Study: 21481243

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 234 mg
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 156 mg
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP) 39 mg
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 21481385

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study: 21481577

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry (IOS) in COPD patients
Number of subjects: 233

Group type: COMPARATOR
Intervention: Impulse oscillometry (IOS) in healthy non-smokers
Number of subjects: 233
Study: 21481640

Group type: EXPERIMENTAL
Intervention: Florbetaben (¹⁸F) PET
Number of subjects: 150
Study: 21481713

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Total carbohydrate intake
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Added sugar intake
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Glycemic load
Number of subjects: 89
Study: 21482186

Group type: EXPERIMENTAL
Intervention: R-miniCHOP (375 mg/m² rituximab, 400 mg/m² cyclophosphamide, 25 mg/m² doxorubicin, 1 mg vincristine, 40 mg/m² prednisone)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: R-miniCHOP
Number of subjects: 150
Study: 21482862

Group type: EXPERIMENTAL
Intervention: Gabapentin plus valacyclovir hydrochloride (1000 mg of valacyclovir 3 times a day for 7 days plus gabapentin starting at 300 mg/d, titrated up to 3600 mg/d).
Number of subjects: 133
Study: 21484766

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) dosage escalation from 200 mg to 400 mg every other week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stable dosage of Certolizumab pegol (CZP) at 400 mg every other week
Number of subjects: 0
Study: 21486866

Group type: EXPERIMENTAL
Intervention: Bortezomib combined with rituximab and dexamethasone
Number of subjects: 16
Study: 21487108

Group type: EXPERIMENTAL
Intervention: High-dose zidovudine (600 mg orally every 6 hours) and valganciclovir (900 mg orally every 12 hours)
Number of subjects: 14
Study: 21487288

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m² on days 1 and 8) and Cisplatin (75 mg/m² on day 1 of each cycle) for three 21-day cycles
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin
Number of subjects: 52
Study: 21488082

Group type: EXPERIMENTAL
Intervention: HCV treatment eligibility for Black patients
Number of subjects: 4469

Group type: EXPERIMENTAL
Intervention: Reasons for treatment ineligibility
Number of subjects: 4469

Group type: COMPARATOR
Intervention: Treatment completion evaluations
Number of subjects: 4469
Study: 21488765

Group type: EXPERIMENTAL
Intervention: Normothermic ex vivo lung perfusion (EVLP) for 4 hours
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (transplanted without EVLP)
Number of subjects: 23
Study: 21489579

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention in 80 obese children
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1-year follow-up in 41 children with increase of SDS-BMI
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison of apelin levels between obese and lean children
Number of subjects: 120
Study: 21489874

Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy with cervical dual injection (technetium and patent blue)
Number of subjects: 133
Study: 21490076

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 11686
Study: 21490142

Group type: EXPERIMENTAL
Intervention: Polyphenol intake from diet
Number of subjects: 4942

Group type: EXPERIMENTAL
Intervention: Hydroxycinnamic acid esters and proanthocyanidins
Number of subjects: 4942

Group type: EXPERIMENTAL
Intervention: Nonalcoholic beverages and fruit
Number of subjects: 4942
Study: 21491290

Group type: EXPERIMENTAL
Intervention: Hepatitis C infection
Number of subjects: 97
Study: 21492424

Group type: EXPERIMENTAL
Intervention: Ultrasound comet-tail sign
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP) with cutoff point 1,000 pg/mL
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Modified Boston criteria
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Combination of ultrasound comet-tail sign and NT-proBNP
Number of subjects: 218
Study: 21492428

Group type: EXPERIMENTAL
Intervention: AlgaeCal 1
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: AlgaeCal 2
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study: 21492763

Group type: EXPERIMENTAL
Intervention: MitraClip treatment
Number of subjects: 107
Study: 21493699

Group type: EXPERIMENTAL
Intervention: Stent placement and tracheobronchoplasty (TBP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Stent placement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tracheobronchoplasty (TBP)
Number of subjects: 12
Study: 21493737

Group type: EXPERIMENTAL
Intervention: GOLD-Unclassified smokers
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: LLN-Unclassified smokers
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Smoking control subjects
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Subjects with COPD
Number of subjects: 2500
Study: 21493789

Group type: EXPERIMENTAL
Intervention: Software-aided image with bone suppression and soft-tissue visualization algorithm
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Software-aided image
Number of subjects: 368

Group type: COMPARATOR
Intervention: Standard radiograph
Number of subjects: 368
Study: 21493817

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 8781

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8781
Study: 21494121

Group type: EXPERIMENTAL
Intervention: SG1 (standard group) - underwent total mesorectal excision (TME) 6 weeks after CRT
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: SG2 (study group) - received 2 cycles of modified FOLFOX-6 (mFOLFOX-6) followed by TME 3 to 5 weeks later
Number of subjects: 144
Study: 21494336

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) at doses of 10, 15, 20, and 30 mg worn for 9 hours per day for 7 weeks
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Patch testing for DRS scores ≥ 6 or persistent DRS scores ≥ 4
Number of subjects: 305
Study: 21494337

Group type: EXPERIMENTAL
Intervention: P4 screener
Number of subjects: 559
Study: 21494838

Group type: EXPERIMENTAL
Intervention: AZD4877 at 16 mg/day (maximum tolerated dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD4877 at 4 mg/day
Number of subjects: 0
Study: 21495023

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 40
Study: 21496339

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT survivors completing a series of questionnaires annually.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures including: Medical Outcomes Study SF-36, FACIT - General, FACIT-Fatigue, FACIT-Spiritual, Psychosocial Adjustment to Illness Scale, Rotterdam Symptom Checklist-Revised, Pittsburgh Sleep Quality Index.
Number of subjects: 0
Study: 21497495

Group type: EXPERIMENTAL
Intervention: Genetic counselling and BRCA genetic testing
Number of subjects: 2000
Study: 21497773

Group type: EXPERIMENTAL
Intervention: Carboplatin-based induction chemotherapy
Number of subjects: 60
Study: 21498606

Group type: EXPERIMENTAL
Intervention: Humanized anti-CD11a antibody treatment (weekly subcutaneous for 16 weeks)
Number of subjects: 6
Study: 21498612

Group type: EXPERIMENTAL
Intervention: Confocal scanning laser ophthalmoscopy (cSLO) imaging modalities
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Fundus camera photographs
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: cSLO imaging
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: FAF imaging
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: IR imaging
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: BR imaging
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: RF imaging
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: CF imaging
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Three-field FAF images
Number of subjects: 458
Study: 21499828

Group type: EXPERIMENTAL
Intervention: Newer EHR with robust clinical decision support
Number of subjects: 17
Study: 21501477

Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: QuantiFERON®-TB Gold In-Tube assay (QFT-IT)
Number of subjects: 166
Study: 21502084

Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily for 8 days
Number of subjects: 12
Study: 21502280

Group type: EXPERIMENTAL
Intervention: Use of clinical guidelines for CVD prevention
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: ESC guidelines
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Global risk calculation tools
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Written charts
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: SCORE equation
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Perceived limitations of global risk equations
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Local healthcare framework sufficiency for primary prevention
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Local healthcare framework sufficiency for secondary prevention
Number of subjects: 806
Study: 21502553

Group type: EXPERIMENTAL
Intervention: Belinostat administered intravenously at 1 g/m(2) on days 1 to 5 of a 21-day cycle until disease progression or development of intolerance.
Number of subjects: 41
Study: 21502650

Group type: EXPERIMENTAL
Intervention: Perioperative myocardial infarction (MI)
Number of subjects: 8351

Group type: EXPERIMENTAL
Intervention: Patients with perioperative MI
Number of subjects: 8351

Group type: COMPARATOR
Intervention: Patients without perioperative MI
Number of subjects: 8351

Group type: EXPERIMENTAL
Intervention: Patients with ischemic symptoms
Number of subjects: 8351

Group type: EXPERIMENTAL
Intervention: Patients without ischemic symptoms
Number of subjects: 8351
Study: 21502953

Group type: EXPERIMENTAL
Intervention: GSK1521498 (0.4-100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NTX (2-50 mg)
Number of subjects: 0
Study: 21503856

Group type: EXPERIMENTAL
Intervention: 1 mg/kg pegnivacogin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: anivamersen (RB007)
Number of subjects: 0
Study: 21504290

Group type: EXPERIMENTAL
Intervention: Lenalidomide monotherapy
Number of subjects: 0
Study: 21504563

Group type: EXPERIMENTAL
Intervention: Masitinib (3 or 6 mg/kg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21504774

Group type: EXPERIMENTAL
Intervention: 3.75 μg HA/AS03(A)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: 1.9 μg HA/AS03(B)
Number of subjects: 454
Study: 21505722

Group type: EXPERIMENTAL
Intervention: Certoparin 3,000U anti Xa o.d.
Number of subjects: 189

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 5,000 IU t.i.d.
Number of subjects: 189
Study: 21507261

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC) for 4 consecutive days after a control challenge with normal saline.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control challenge (normal saline).
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC) for 4 consecutive days.
Number of subjects: 32
Study: 21508089

Group type: EXPERIMENTAL
Intervention: Maltodextrins and leucine (0.035 g . kg(-1) . h(-1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Maltodextrins (0.25 g . kg(-1) . h(-1))
Number of subjects: 11
Study: 21508120

Group type: EXPERIMENTAL
Intervention: Non-myeloablative conditioning and allogeneic hematopoietic cell transplantation with post-grafting imatinib for Philadelphia chromosome-positive disease
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Non-myeloablative conditioning and allogeneic hematopoietic cell transplantation
Number of subjects: 51
Study: 21508125

Group type: EXPERIMENTAL
Intervention: Bone marrow analysis in patients with MonoMAC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis in patients with MonoMAC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Presence of plasma cells in patients with MonoMAC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: T-cell large granular lymphocyte populations in patients with MonoMAC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chromosomal breakage studies and sequencing in patients with MonoMAC
Number of subjects: 18
Study: 21508251

Group type: EXPERIMENTAL
Intervention: Body talk among social contacts
Number of subjects: 60
Study: 21508413

Group type: EXPERIMENTAL
Intervention: ⁹⁰Y-ibritumomab tiuxetan, fludarabine, and 2 Gy total body irradiation
Number of subjects: 40
Study: 21508633

Group type: EXPERIMENTAL
Intervention: eGFR(Cys)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: eGFR(Cr)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 476